Wisp Launches Groundbreaking Male BV Partner Treatment

The Leading Women’s Telehealth Provider is the First to Bring Revolutionary Regimen to Market in Response to New Study on Bacterial Vaginosis

NEW YORK--(BUSINESS WIRE)--Wisp, the largest pure play women's telehealth company in the U.S. focused on providing sexual and reproductive health solutions, now serving more than 1.4 million patients, today launched the first-ever Male BV Partner Treatment. This launch comes in response to new evidence supporting that bacterial vaginosis (BV) can be sexually transmitted. Wisp patients and their partners can now access this two part paired prescription regimen that, in recent findings, has shown to be effective in treating this infection.

1 in 3 women are affected by BV with 60 percent of BV cases recurring within a year. This may be due to the fact that male partners were not being tested nor treated for the infection, passing BV back and forth. Recent research in a peer-reviewed medical journal found that combined oral and topical antimicrobial therapy for male partners in addition to first-line treatment of women for BV resulted in a lower rate of recurrence of the infection within 12 weeks compared to standard antibiotic care delivered to females alone.

“For too long, BV has been thought of as a women’s-only issue, leaving the sexual partner untreated and women stuck in a long, frustrating cycle of antibiotics," said Monica Cepak, Wisp CEO. “This decision to quickly act on new research reflects Wisp's commitment to advancing women’s health, improving access to treatment, and advocating for improved care outcomes. We will continue to monitor emerging data to ensure safe and effective treatment options are available to our patients.”

Wisp’s treatment recommendation is for patients assigned male at birth, who are in an ongoing sexual relationship with a partner assigned female at birth, who is receiving prescription treatment or a confirmed current diagnosis for BV. Patients who have stated that they wish to receive treatment alongside their female partners to help positively impact treatment outcomes for their female partner with topical Clindamycin and oral Metronidazole are prescribed oral Metronidazole 500 milligrams twice daily for seven days along with Topical Clindamycin 2 percent cream 2.5 grams topically to the external penile skin twice daily for seven days. Both of these treatments should be taken together simultaneously for the full seven days.

“At Wisp, we’re committed to advancing women's health by improving access to innovative treatment options. Emerging high-quality evidence shows that combining oral Metronidazole and topical Clindamycin for male partners may have a positive impact on limiting female bacterial vaginosis. We believe this proactive approach has the potential to improve outcomes for you and your partner,” said Dr. Jillian Lopiano, OBGYN & Chief Health Officer at Wisp.

Consistently being the first to bring innovative solutions to market, Wisp has pioneered the launch of products like DoxyPEP in response to CDC recommendations in 2023 supporting the use of the ‘morning after pill’ to treat STIs. These quick reactions underscore Wisp’s commitment to serving patients with best-in-class treatments that are accessible and affordable. With BV being the provider’s largest category, Wisp continues to see massive demand for products that address this infection as the category continues to grow at high rates year-over-year. The company looks to expand offerings in this category, with plans to launch its diagnostics vertical later this year.

ABOUT WISP:

Wisp is the largest pure play women’s telehealth company in the U.S. focused on providing sexual and reproductive health solutions to its more than 1.4 million patients in all 50 states. Offering discreet treatments online with a comprehensive selection of first-to-market products and telehealth services, Wisp has solidified itself as the one-stop shop for all women’s health needs.

Wisp is committed to making women’s healthcare more inclusive, cost-effective, and accessible for all, addressing all stages of her healthcare journey, from her birth control, to fertility, menopause, STI diagnostics, weight care and more. Wisp has been named Fast Company’s Most Innovative Companies of 2023 and Inc.’s Best in Business in 2024. Wisp is a growing and profitable company and is majority-owned by WELL Health Technologies Corp. To learn more, please visit hellowisp.com or follow @hellowisp on Facebook, Instagram, TikTok and YouTube.